A comparative study of the hypolipidaemic effects of a new polysaccharide, mannan <i>Candida albicans</i> serotype A, and atorvastatin in mice with poloxamer 407-induced hyperlipidaemia

Короленко, Т. А.; Johnston, Thomas P.; Лыков, А. П.; Shintyapina, Alexandra; Khrapova, M. V.; Гончарова, Н. В.; Korolenko, E. C.; Bgatova, Nataliya; Machová, Eva; Neščaková, Zuzana; Сахно, Л. В.

doi:10.1111/jphp.12633

Cited by 10 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Average CHIT1 activity in serum remained constant after 6 months of cholesterol-and triglyceride-lowering treatment with atorvastatin or bezafibrate, suggesting that LDL cholesterol and triglyceride reduction obtained with both drugs did not modify macrophage CHIT1 expression/activity in these subjects. Correction of the plasma lipid profile does not seem to affect the CHIT1 expression level in vivo, supporting the idea that CHIT1 activity cannot be used to monitor progression of atherosclerosis [38][39][40][41][42][43] .…”

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 54%

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Bargagli¹,

Rosi²,

Lavorini³

et al. 2017

Pathobiology

View full text Add to dashboard Cite

Sarcoidosis is a systemic granulomatous disease of unknown etiology. Recent studies demonstrated that its pathogenesis is related with enhanced oxidative stress (protein carbonylation and lipid peroxidation) and alterations in the circulating lipid profile. Alterations of lipid metabolism (including the reduction in high-density lipoprotein cholesterol levels and apolipoprotein A1 concentrations) induce plasma membrane, bronchial and lung capillary endothelial cell damage in sarcoidosis patients. Dyslipidemia is associated with increased oxidative stress, diminished overall antioxidative protection and increased risk for atherosclerosis. Very recently increased cardiovascular biomarkers (in particular alterations of lipoprotein A and d-dimer concentrations) were observed in sarcoidosis patients, mainly in those with a high risk of atherosclerosis. Chitotriosidase, a biomarker of sarcoidosis activity and macrophage activation, is increased in serum and bronchoalveolar lavage fluid of patients with sarcoidosis as well as in patients with atherosclerosis. Lipidomics and other recent methodologies allowed the discovery of proteins involved in lipid metabolism and sarcoidosis pathogenesis, such as serum amyloid A, a biomarker of sarcoidosis activity, involved in innate immune response, inflammation and apolipoprotein metabolism. In this review lipid metabolism alteration and atherosclerosis risk in sarcoidosis patients were discussed in order to contribute to this novel and interesting research topic.

show abstract

Section: Chitotriosidase In Atherosclerosis and Sarcoidosismentioning

confidence: 54%

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Bargagli¹,

Rosi²,

Lavorini³

et al. 2017

Pathobiology

View full text Add to dashboard Cite

show abstract

“…The expression of chitinases [chitotriosidase (CHIT1) and acid mammalian chitinase (CHIA)] was assayed by a reverse-transcription quantitative polymerase chain reaction (RT-qPCR), as described earlier [ 35 , 36 ].…”

Section: Methodsmentioning

confidence: 99%

Trehalose Activates Hepatic and Myocardial Autophagy and Has Anti-Inflammatory Effects in db/db Diabetic Mice

Короленко¹,

Ovsyukova²,

Bgatova

et al. 2022

Life

View full text Add to dashboard Cite

Db/db mice (carrying a mutation in the gene encoding leptin receptor) show autophagy suppression. Our aim was to evaluate the effect of autophagy inducer trehalose on liver and heart autophagy in db/db mice and to study inflammation dysregulation and the suitability of chitinases’ expression levels as diabetes markers. Thirty-eight male db/db mice and C57/BL mice (control) were used. The db/db model manifested inflammation symptoms: overexpression of TNF-α in the spleen and underexpression of IL-10 in the liver and spleen (cytokine imbalance). Simultaneously, we revealed decreased expression of chitotriosidase (CHIT1) and acid mammalian chitinase (CHIA) in the liver of db/db mice. CHIA expression in db/db mice is significantly lower only in the spleen. Trehalose treatment significantly reduced blood glucose concentration and glycated hemoglobin. Treatment of db/db mice by trehalose was followed by increased autophagy induction in the heart and liver (increased autolysosomes volume density studied by morphometric electron-microscopic method). Trehalose exerted beneficial cardiac effects possibly via increased lipophagy (uptake of lipid droplets). The autophagy activation by trehalose had several positive effects on the heart and liver of db/db mice; therefore, lipophagy activation seems to be a promising therapy for diabetes.

show abstract

“…Mannan is a molecule supporting the effective elimination of circulating lipoproteins [34,39]. In our study, the mannan of C. albicans serotype A was used in a dose of 50 mg/kg (5×) or 100 mg/kg (2×) before acute lipemia was induced by the single administration of poloxamer 407 (250–300 mg/kg).…”

Section: Mannans: Biological Function and Role In Pathologymentioning

confidence: 99%

Glucan and Mannan—Two Peas in a Pod

Короленко

Bgatova

Větvička

2019

IJMS

View full text Add to dashboard Cite

In recent decades, various polysaccharides isolated from algae, mushrooms, yeast, and higher plants have attracted serious attention in the area of nutrition and medicine. The reasons include their low toxicity, rare negative side effects, relatively low price, and broad spectrum of therapeutic actions. The two most and best-studied polysaccharides are mannan and glucan. This review focused on their biological properties.

show abstract

A comparative study of the hypolipidaemic effects of a new polysaccharide, mannan Candida albicans serotype A, and atorvastatin in mice with poloxamer 407-induced hyperlipidaemia

Abstract: It is suggested that mannan serotype A, like β-glucan, may represent another hypolipidaemic agent, which could potentially be used as an adjunctive therapy with conventional antihyperlipidaemic drugs (statins and fibrates) in humans.

Cited by 10 publications

References 33 publications

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Increased Risk of Atherosclerosis in Patients with Sarcoidosis

Trehalose Activates Hepatic and Myocardial Autophagy and Has Anti-Inflammatory Effects in db/db Diabetic Mice

Glucan and Mannan—Two Peas in a Pod

Contact Info

Product

Resources

About